Studies of the Efficacy of Cereton in Mild Cognitive Impairment of the Amnestic Type Based on Testing Lipid Markers

التفاصيل البيبلوغرافية
العنوان: Studies of the Efficacy of Cereton in Mild Cognitive Impairment of the Amnestic Type Based on Testing Lipid Markers
المؤلفون: Selezneva Nd, Gavrilova Si, Ya. B. Fedorova, E. V. Ponomareva, U A Gutner, A. V. Alesenko, I. V. Kolykhalov, M. A. Shupik, A. O. Lebedeva
المصدر: Neuroscience and Behavioral Physiology. 49:147-152
بيانات النشر: Springer Science and Business Media LLC, 2018.
سنة النشر: 2018
مصطلحات موضوعية: 0301 basic medicine, chemistry.chemical_classification, medicine.medical_specialty, Ceramide, General Neuroscience, Metabolite, Ceramidase, Sphingolipid, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, Enzyme, Endocrinology, chemistry, Internal medicine, Phosphatidylcholine, medicine, Acid sphingomyelinase, Sphingomyelin, 030217 neurology & neurosurgery, medicine.drug
الوصف: Objectives. To determine the efficacy and safety of treatment with Cereton (alfoscerate) in patients with mild cognitive impairment syndrome (MCI) and its effects during and after treatment on phosphatidyl-choline, sphingomyelin, and ceramide (a sphingolipids metabolite) contents and the activity of genes controlling the synthesis of enzymes (sphingomyelinase and ceramidase) involved in the sphingomyelin and ceramide metabolism. Materials and methods. A total of 20 patients (14 women, six men) aged 51–82 (mean 70.3 ± 9.1) years were studied. Patients’ status corresponded to the criteria for diagnosis of MCI syndrome of the anamnestic type. Plasma phosphatidylcholine, sphingomyelin, and ceramide were estimated by thin layer chromatography, while expression of the sphingomyelinase and ceramidase genes was determined using the reverse transcriptase polymerase chain reaction. Results and conclusions. Sharp increases in the contents of phosphatidylcholine and ceramide – hydrolysis products of sphingomyelin – were seen. Expression of the genes (acid sphingomyelinase and ceramidase) controlling ceramide metabolism decreased in most patients during Cereton treatment. Increases in the levels of phosphatidylcholine and decreases in the expression of ceramide metabolism genes during treatment with Cereton and other agents affecting phosphatidylcholine and sphingomyelin metabolism can be used as markers for treatment efficacy.
تدمد: 1573-899X
0097-0549
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ca2067db822dea68724120b877a4accd
https://doi.org/10.1007/s11055-018-0708-z
حقوق: CLOSED
رقم الأكسشن: edsair.doi...........ca2067db822dea68724120b877a4accd
قاعدة البيانات: OpenAIRE